New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTSPPI, LGNDSpectrum gains rights to Capitsol-enabled Melphalan
Spectrum Pharmaceuticals (SPPI) has gained global development and commercialization rights to Ligand Pharmaceuticalsí (LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
News For SPPI;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
08:03 EDTSPPINavidea names Gonzalez CEO
Subscribe for More Information
October 8, 2014
11:11 EDTLGNDLigand Q3 pre-announcement unlikely to rally stock, says Cantor
Cantor said its views Ligand's pre-announcement of better than expected Q3 results as no more than "a shuffling of the deck chairs" since the company did not also raise its view for the fiscal year. The firm said it does not expect upward momentum for the stock in the near-term and maintains its Hold rating on the shares.
08:34 EDTLGNDLigand maintains FY14 adjusted EPS $1.50-$1.55, consensus $1.55
Subscribe for More Information
08:33 EDTLGNDLigand sees Q4 revenue $22.5M-$24.5M, consensus $23.54M
08:33 EDTLGNDLigand sees Q3 adjusted EPS 33c-37c, consensus 32c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use